文献速递甲状腺疾病

甲状腺激素抵抗综合征的产前诊断及其临床意义

Prenatal Diagnosis of Resistance to Thyroid Hormone and Its Clinical Implications.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本文为回顾性病历分析,纳入13名携带THRB基因突变的女性共18次妊娠,通过羊膜腔穿刺进行产前基因诊断。携带野生型胎儿的孕妇可选择抗甲状腺药物治疗,目标为血清游离甲状腺素不超过正常上限的20%。结果显示野生型与甲状腺激素抵抗β型婴儿在校正胎龄的出生体重和出生时血清促甲状腺激素水平上无显著差异。

要点

  • 对甲状腺激素抵抗β型孕妇所怀野生型胎儿行产前基因诊断有助于指导妊娠期管理。
  • 将野生型胎儿孕妇的游离甲状腺素维持在正常上限50%以下似乎是审慎的做法。
  • 该做法可预防原本预期的低出生体重和出生后促甲状腺激素抑制。

核心结论

  • 产前诊断可能在甲状腺激素抵抗β型妊娠期管理中发挥重要作用。
  • 对携带野生型胎儿的甲状腺激素抵抗β型孕妇,将母体游离甲状腺素控制在不超过正常上限50%似乎是审慎的做法,可预防原本预期的低出生体重和出生后促甲状腺激素抑制。

研究设计与样本

  • 回顾性病历分析,纳入13名携带THRB基因突变的女性共18次妊娠,在学术机构并联合院外医院和私人诊所进行。

主要发现

  • 甲状腺激素抵抗β型母亲所生的野生型与甲状腺激素抵抗β型婴儿之间,校正胎龄的出生体重和出生时血清促甲状腺激素水平均无显著差异。

关键数值与推荐

  • 携带野生型胎儿的孕妇由其治疗医生选择抗甲状腺药物治疗,目标为避免血清游离甲状腺素超过正常上限的20%。
  • 结论提出将携带野生型胎儿的甲状腺激素抵抗β型孕妇的母体游离甲状腺素控制在不超过正常上限50%似乎是审慎的做法。

临床怎么用

  • 对甲状腺激素抵抗β型孕妇可通过羊膜腔穿刺行产前基因诊断,以识别野生型胎儿并指导妊娠期管理。
  • 携带野生型胎儿的孕妇可考虑抗甲状腺药物治疗以控制母体游离甲状腺素水平,具体目标阈值原文分别提及20%和50%的正常上限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Resistance to thyroid hormone-β (RTH-β) is an autosomal dominant disorder characterized by reduced sensitivity of target tissues to thyroid hormones (THs). Individuals with RTH-β have high TH levels usually due to mutations in the TH receptor-β (THRB) gene. The management of RTH-β during pregnancy is challenging, as wild-type (WT) fetuses born to RTH-β mothers have low birth weight and suppressed postnatal thyroid-stimulating hormone (TSH), due to intrauterine exposure to excess TH. OBJECTIVE: To determine birth weight and postnatal TSH of WT fetuses carried by mothers with RTH-β whose fT4 levels were maintained below 20% of the upper limit of normal (ULN). DESIGN: Retrospective chart review. SETTING: Academic institution in collaboration with off-site hospitals and private practices. PATIENTS: Thirteen women harboring THRB gene mutations were evaluated during 18 pregnancies. INTERVENTION: Prenatal genetic diagnosis by amniocentesis. Women carrying WT fetuses were given the option of treatment with antithyroid medication by their treating physicians with the aim to avoid serum fT4 levels above 20% of the ULN. RESULTS: No significant difference was found in birth weight corrected for gestational age and in serum TSH levels at birth between WT and RTH-β infants born to RTH-β mothers. CONCLUSIONS: Prenatal diagnosis may play an important role in the management of RTH-β during pregnancy. Aiming for maternal fT4 levels not above 50% of the ULN in RTH-β mothers carrying WT fetuses seems to be a prudent approach that prevents the otherwise expected low birth weight and postnatal TSH suppression.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pappa T, Anselmo J, Mamanasiri S, et al. Prenatal Diagnosis of Resistance to Thyroid Hormone and Its Clinical Implications. J Clin Endocrinol Metab. 2017. PMID: 28938413. doi:10.1210/jc.2017-01251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。